HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Rh deficiency syndrome — Clinical Guidelines

Overview

Rh deficiency syndrome, more accurately referred to as Rh D alloimmunization, occurs when Rh-negative individuals develop antibodies against Rh-positive fetal red blood cells, potentially leading to hemolytic disease of the newborn.

Diagnosis

Detection of Rh-positive fetal cells in maternal circulation through fetomaternal hemorrhage tests 5.

Serological testing for Rh antibodies in maternal blood 1 2.

Management

Postpartum administration of Rh D immune globulin to prevent maternal sensitization after delivery 2 3.

Antepartum administration of Rh D immune globulin to further reduce the risk of alloimmunization 2 3.

Administration of Rh D immune globulin within 72 hours following any sensitizing event (e.g., miscarriage, trauma) 4.

Special Populations

Pregnancy: Routine antepartum and postpartum administration of Rh D immune globulin is recommended to prevent alloimmunization 1 2 3.

Non-specific guidance for pediatrics and elderly populations; focus primarily on preventing sensitization during pregnancy 1 2.

Key Recommendations

Do not administer Rh D immune globulin before 12 weeks of gestation to prevent Rh D alloimmunization in the event of early pregnancy loss in Rh-negative women 1 (Evidence: Expert opinion).

Routine postpartum administration of Rh D immune globulin is strongly recommended to reduce the risk of Rh D alloimmunization 2 (Evidence: Strong).

Include antepartum administration of Rh D immune globulin for further reduction of alloimmunization risk 2 (Evidence: Strong).

Administer Rh D immune globulin within 72 hours following any sensitizing event to ensure effective prophylaxis 4 (Evidence: Moderate).

References

1 Maurice P, Vigoureux S, Garabedian C, Sibiude J, Sananès N. Prevention of RhD alloimmunization in the first trimester of pregnancy: Clinical practice guidelines of the French College of Obstetricians and Gynecologists. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2025. link 2 . Practice Bulletin No. 181: Prevention of Rh D Alloimmunization. Obstetrics and gynecology 2017. link 3 . Practice Bulletin No. 181 Summary: Prevention of Rh D Alloimmunization. Obstetrics and gynecology 2017. link 4 Wee WW, Kanagalingam D. The use of anti-D immunoglobulins for rhesus prophylaxis: audit on knowledge and practices among obstetricians. Singapore medical journal 2009. link 5 McWilliam AC, Davies SC. Detection of fetomaternal haemorrhage by an immunofluorescence technique. Journal of clinical pathology 1985. link 6 Nicolson GL, Masouredis SP, Singer SJ. Quantitative two-dimensional ultrastructural distribution of Rh o (D) antigenic sites on human erythrocyte membranes. Proceedings of the National Academy of Sciences of the United States of America 1971. link

Rh deficiency syndrome